Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
30 mars 2023 07h00 HE
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
30 mars 2023 04h24 HE
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune is selected for the first cohort of the French Tech Health20 program
27 mars 2023 07h32 HE
|
Smart Immune
Smart Immune is selected for the first cohort of the French Tech Health20 program This unique program has selected 20 French start-ups that offer disruptive healthcare innovations PARIS, France,...
Smart Immune appoints world-class Clinical Advisory Board
21 nov. 2022 07h00 HE
|
Smart Immune
Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
13 oct. 2022 07h00 HE
|
Smart Immune
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers First trial...
Smart Immune Bolsters Management Team with Medical and Technical Appointments
13 sept. 2022 07h00 HE
|
Smart Immune
Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...
Smart Immune appoints world-leading experts to its Scientific Advisory Board
28 juil. 2022 07h00 HE
|
Smart Immune
Smart Immune appoints world-leading expertsto its Scientific Advisory Board PARIS, France, July 28, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a...
Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board
06 juil. 2022 07h25 HE
|
Smart Immune
Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board PARIS, France, July 6, 2022 – Smart Immune SAS, a clinical-stage biotechnology...
Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022
20 mai 2022 06h00 HE
|
Smart Immune
PARIS, May 20, 2022 (GLOBE NEWSWIRE) -- Smart Immune, a clinical-stage biotechnology company focused on saving and improving lives by delivering to patients a new generation of thymus-empowered T...
Smart Immune Announces Research Collaboration with Memorial Sloan Kettering Cancer Center (MSK) to Expedite Development of a Next Generation CAR-T Through its Long Lasting, Exhaustion-Free CAR ProTcell™ Platform
09 déc. 2021 05h30 HE
|
Smart Immune
PARIS, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a clinical stage T-cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus-in-a-dish” technology to develop T-cell...